Entry Rationale
With the positive news of clinical success and the current price being near the 20-day low support level ($40.29), there is a secured downside rigidity, making it a consideration for purchase.
V12 SENTINEL ENGINE
All AI Trading Journal Entries
DFTXAI Trading Journal · 2026-08-19
A transaction that exceeded the target due to the positive news of clinical success and a rebound at the support level.
Definium succeeds in late-stage trial for LSD-derived psychiatric therapy
ENTRY PRICE$40.91Entry reference price
AI PREDICTION+4.5%Predicted upside
VERIFIED RESULT12.9%12.9% up
PREDICTION GAP+8.4%pGap vs. actual result
CONFIDENCE85AI analysis confidence
Definium has successfully completed late-stage clinical trials for its LSD derivative psychedelic therapy.
02
INITIAL SCENARIO
AI's Initial Call
Target/Stop Scenario
Enter based on the belief in the clinical success news and the support level of $40.29, but if the stock price breaks down and falls below the stop-loss level of $40.29, I will immediately cut losses. Conversely, if it reaches the resistance level of $49.70, I will take profits.
Take-profit reference$49.70
Stop-loss reference$40.29
03
TECHNICAL BASELINE
Market Data at Analysis Time
MA20$43.67MA60$35.56MA200$22.2
The technical indicators at the entry point show an RSI(14) of 41.9 (neutral zone), a positive alignment of moving averages, a trading volume that is 1.94 times the 20-day average, and a recent 7-day volatility of -6.0%.
04
HISTORICAL EVIDENCE
Similar Past Cases
As past similar success cases, there is the same stock DFTX with the keyword 'LSD' overlapping, which had a trade on 2026-08-19 (return of 12.9%). Although there is no direct similarity, for reference on top performance in the region, there are cases of VEEE (return of 451.7%) and LRCX (return of 346.8%).
Reviewing Prediction vs. Actual Result
The trade, which entered with a forecasted return of 4.5%, ultimately recorded an actual return of 12.9%, resulting in an OVERHIT designation. The assessment that the current price is near the 20-day low support level ($40.29) provided a solid basis for downside rigidity, bolstered by the certainty of clinical success news. The trading volume reached 1.94 times the 20-day average, and the alignment of moving averages supported the influx of buying interest. Consequently, the rebound towards the resistance level ($49.70) was stronger than anticipated, leading to results that exceeded the forecast.
What to Watch in the Next Analysis
Through this trading activity, we have once again confirmed the pattern where the potential for a technical rebound near support levels and signals of increased trading volume lead to actual synergy when positive news occurs. In future trading, we will consistently apply the principle of selecting intervals that satisfy both the presence of news catalysts and the downside rigidity near key support levels (such as $40.29). Additionally, we will complement our strategic flexibility by keeping the possibility of reaching target prices more open when the impact of positive news is significant.
05
V13 VERIFICATION
V13 Worker auto-verifiedChart Verification
Initial ChartAt Analysis · 2026-08-19
$40.91Verification ChartVerification · 2026-08-19 11:38:08
12.9%Investment Reference NoticeThis report is a record of past AI analysis being verified — it does not solicit buying or selling any specific stock. All investment decisions and responsibility rest with the user.